EUVIMEDEUVIMED entdecken
Crossref

ETCTN 10558: A Phase II Randomized Control Trial of Triapine Plus Lutetium 177 Dotatate Versus Lutetium 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors

Aman Chauhan, Bhavana Konda, Heidi Weiss, Heloisa Soares, Daneng Li, James Yao, Benson Al Bowen, Elizabeth Popa, Katherine Hitchcock, Matthew Deek, Sam Lubner, Edward Kim und 8 weitere

Endocrine Abstracts · 04.03.2026

DOI: 10.1530/endoabs.116.t15 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine Abstracts, online erschienen am 04.03.2026. Verfasst von Aman Chauhan und 19 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Chauhan, A., Konda, B., Weiss, H., Soares, H., Li, D., Yao, J., Bowen, B. A., Popa, E., Hitchcock, K., Deek, M., Lubner, S., Kim, E., Zhang, J., Kunos, C., Ivy, P., Gore, S., Pelosof,, L., Kohn, E., Arnold, S., & Anthony, L. (2026). ETCTN 10558: A Phase II Randomized Control Trial of Triapine Plus Lutetium 177 Dotatate Versus Lutetium 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors. Endocrine Abstracts. https://doi.org/10.1530/endoabs.116.t15

Vancouver

Chauhan A, Konda B, Weiss H, Soares H, Li D, Yao J, et al. ETCTN 10558: A Phase II Randomized Control Trial of Triapine Plus Lutetium 177 Dotatate Versus Lutetium 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors. Endocrine Abstracts. 2026. doi:10.1530/endoabs.116.t15

BibTeX
@article{Chauhan2026,
  author = {Chauhan, Aman and Konda, Bhavana and Weiss, Heidi and Soares, Heloisa and Li, Daneng and Yao, James and Bowen, Benson Al and Popa, Elizabeth and Hitchcock, Katherine and Deek, Matthew and Lubner, Sam and Kim, Edward and Zhang, Janie and Kunos, Charles and Ivy, Percy and Gore, Steven and Pelosof,, Lorraine and Kohn, Elise and Arnold, Susanne and Anthony, Lowell},
  title = {ETCTN 10558: A Phase II Randomized Control Trial of Triapine Plus Lutetium 177 Dotatate Versus Lutetium 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors},
  journal = {Endocrine Abstracts},
  year = {2026},
  doi = {10.1530/endoabs.116.t15}
}
Kostenlos starten →